Aristotle University Of Thessaloniki (AUTH)
Εβδομαδιαία συνεχής καταγραφή των επιπέδων γλυκόζης σε χρόνιους αιμοκαθαιρόμενους διαβητικούς ασθενείς: συγκριτική μελέτη δύο διαλυμάτων αιμοκάθαρσης
Abstract
dc:descriptionDiabetes mellitus (DM) is the first cause of End-Stage Kidney Disease (ESKD). DM regulation has many peculiarities and difficulties in patients with ESKD. Especially in HD diabetes patients there are many factors, but mainly there is the glucose elimination from the dialysis filter, they make the DM management even more difficult. These patients have a higher risk of developing day-to-day glucose variability, hypoglycemic episodes and even not diagnosed asymptomatic hypoglycemic episodes, which associated with increased mortality. The use of glucose-free dialysis solution contributes to increased glucose loss, especially in patients with unregulated DM, and increases the incidence of hypoglycemia during dialysis. Glycated hemoglobin (HbA1c), which has been established as the ideal glycemic index worldwide, presents several limitations in its use for patients with DM and ESKD. In addition, HbA1c does not take into account changes in glucose during the day. In recent years we have latest technologies of continuous glucose monitoring (CGM) systems, which they are devices that measure glucose by continuous measurements in the subcutaneous tissue. Also, newer glycemic indexes, such as glycated albumin (GA) and serum glycated protein (SGP) are now being evaluated for the assessment of DM regulation. The purpose of the present comparative study between two different dialysis solutions (glucose free vs 100mg/dl glucose) is to evaluate and better regulate patients with type 2 DM undergoing HD, utilizing the latest technology of Medronic's iPro CGM. Also, the study evaluate the latest glycemic indexes GA and SGP as alternative markers for HbA1c to determine the glycemic status of diabetic patients on HD.. The final study population consisted of 36 patients, who were fitted with a 7-day CGM. Phase A of the study corresponds to 3 consecutive weekly dialysis sessions with glucose free solution and phase B with 100mg/dl glucose solution respectively. Comparison of the two phases A and B showed that the addition of glucose solution to the 4 hour HD period helps to avoid blood glucose lowering (p <0.001), and avoid the risk of hypoglycaemia during the HD session (p <0.001). However, does not appear to be involved in modifying the overall mean glucose, but it seems to reduce the variability of glucose in long term time periods. Finally, the present study showed that GA has higher sensitivity and specificity (r: 0.884, p <0.001) and was more strongly correlated with mean glucose compared to SGP and HbA1c (r: 0.672, p <0.001 and r: 0.694, p <0.001).According to the above results of the present study it is found that CGM system is the only method that accurately records the significant fluctuations in blood sugar levels of hemodialysis patients. Although it is the largest comparative study with a CGM system until today, larger documented research studies are needed with the use of CGM in HD diabetes patients to expand our knowledge in the control of diabetes and the high risk of its complications.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Divani, Maria
- Διβάνη, Μαρία
Subjects
dc:subject × 16- Συστήματα συνεχούς καταγραφής γλυκόζης (CGM)
- Αιμοκάθαρση
- Σακχαρώδης διαβήτης
- Γλυκοζυλιωμένη αιμοσφαιρίνη (HbA1c)
- Γλυκοζυλιωμένη αλβουμίνη (GA)
- Γλυκοζυλιωμένη πρωτεΐνη (SGP)
- Continuous glucose monitoring (CGM) system
- Hemodialysis (HD)
- Diabetes mellitus
- Glycated hemoglobin (HbA1c)
- Glycated albumin (GA)
- Serum glycated protein (SGP)
- Ιατρική και Επιστήμες Υγείας
- Επιστήμες Υγείας
- Medical and Health Sciences
- Health Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/46415